Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (526)	3/17/1999 11:40:00 PM
From: aknahow	Respond to of 4974

German Schering plans biotech buy. 18 March story in financial Times of London. Won't cut & paste. ft.com

To: scaram(o)uche who wrote (526)	3/18/1999 7:53:00 PM
From: nigel bates	Read Replies (1) \| Respond to of 4974

...nominate this one, as I'm sort of fond of Chiroscience - biz.yahoo.com (and can't understand the lack of interest after the Chirocaine approval). nig

To: scaram(o)uche who wrote (526)	3/24/1999 12:44:00 AM
From: John Starks	Read Replies (1) \| Respond to of 4974

Richard, RE: ENMD and the ATP synthetase study <<Yes, that's correct. The significance of the work "extends" from the biological observations of others. Look at table 2 and tell me that you're impressed by the internal rationale of looking at the molecule.>> sorry for the slow response time. You are right, the data you refer to is nothing to write home about. However, not to get too philosophical, but doesn't all science build on existing work? I am still impressed with the tumor shrinking in vivo and it will take more than underwhelming HUVEC culture results to dampen my optimism. John